# PATL2 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- PATL2 is an RNA-binding protein crucial for translational repression and mRNA homeostasis, particularly in mammalian oogenesis and early embryogenesis. Biallelic loss-of-function mutations in PATL2 are a monogenic cause of female infertility, specifically Oocyte Maturation Defect-4 (OOMD4), characterized by the production of immature oocytes arrested at the germinal vesicle (GV) stage.

- The PATL2 gene is located at chromosomal locus 15q21.3 and comprises 16 exons. Its protein product, a 545-amino-acid protein, possesses an N-terminal Pat1 domain, a central RNA-binding region with two RRMs, and a C-terminal Pat1 core domain essential for translational repression and recruitment of the CCR4-NOT deadenylase complex.

- Pathogenic PATL2 variants, predominantly missense, nonsense, and frameshift mutations, are concentrated in the RNA-binding and C-terminal core domains. These mutations lead to loss-of-function, disrupting the timely translation of maternal mRNAs encoding critical cell cycle regulators like CDC20 and BUB1, thereby preventing meiotic resumption.

- Clinical diagnosis of OOMD4 relies on identifying biallelic pathogenic PATL2 variants via genetic testing (e.g., targeted gene panels, WES) in women with primary infertility and consistent GV-stage oocyte arrest despite normal endocrine profiles and ovarian reserve.

- Therapeutic strategies for PATL2-related infertility are limited; however, spindle transfer (ST), which replaces the patient's oocyte spindle into a donor oocyte with functional PATL2, has shown promise in preclinical models by rescuing developmental competence.

- Emerging evidence suggests PATL2's role extends beyond reproduction, potentially participating in broader cellular processes like cell cycle regulation and stress response, though these functions are less characterized.

---

## Executive Summary & Key Metadata

PATL2 (Protein Associated with Topoisomerase II Homolog 2) is an RNA-binding protein that functions as a critical translational repressor and mRNA homeostasis regulator during mammalian oogenesis and early embryogenesis. The gene was first characterized in humans through whole-exome sequencing studies of women with oocyte meiotic deficiency (OMD), where biallelic loss-of-function mutations were identified as a monogenic cause of female infertility [<a href="#ref-1">1</a>]. PATL2 belongs to the Pat1 family of proteins, which are conserved from yeast to humans and share a characteristic N-terminal Pat1 domain and C-terminal Pat1 core domain. In humans, PATL2 is specifically and highly expressed in oocytes, where it orchestrates the temporal and spatial regulation of maternal mRNA translation—a process essential for meiotic resumption, oocyte maturation, and subsequent embryonic development [1, 1].

The clinical significance of PATL2 is underscored by its association with oocyte maturation defect-4 (OOMD4; OMIM #617743), an autosomal recessive disorder characterized by the production of immature oocytes that fail to progress from the germinal vesicle (GV) stage to metaphase II (MII). Affected women typically present with primary infertility, normal endocrine profiles, and repeated failed assisted reproductive technology (ART) cycles [1, 1, 1]. Beyond its canonical role in reproduction, emerging evidence suggests that PATL2 may participate in broader cellular processes, including cell cycle regulation and stress response, although these functions remain less well characterized [<a href="#ref-1">1</a>].

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | PATL2 |
| UniProt Accession | C9JE40 |
| Representative PDB ID | true (homology models available; experimental structure pending) |
| Chromosomal Locus | 15q21.3 |
| Gene Size | ~38.5 kb (genomic) |
| mRNA Length | ~2,900 nt (canonical transcript) |
| Protein Length | 545 amino acids (canonical isoform) |
| Primary Molecular Function | RNA binding; translational repression; mRNA decapping activator |
| Subcellular Localization | Cytoplasm; P-body associated |
| Expression Pattern | Oocyte-specific (human); also detected in early embryos |
| Disease Associations | Oocyte maturation defect-4 (OOMD4); female infertility; early embryonic arrest |
| Inheritance Pattern | Autosomal recessive |
| OMIM Phenotype | 617743 |
| ClinVar Variants | >50 pathogenic/likely pathogenic variants reported |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The PATL2 gene is located on the long arm of chromosome 15 at band q21.3 (chr15: 49,523,000–49,561,500; GRCh38/hg38 assembly). The gene spans approximately 38.5 kilobases of genomic DNA and is oriented on the minus strand. The genomic architecture comprises 16 exons and 15 introns, with the translation initiation codon located in exon 1 and the termination codon in exon 16 [1, 1]. The canonical transcript (NM_001145113.2) is 2,897 nucleotides in length and encodes a 545-amino-acid protein with a predicted molecular mass of approximately 60.5 kDa.

The PATL2 locus resides within a gene-dense region of chromosome 15 that includes several other genes implicated in reproductive biology and neurodevelopment. The immediate genomic neighborhood includes *SNAP23* (synaptosome-associated protein 23) and *GCNT3* (glucosaminyl transferase 3) on the centromeric side, and *MYO5C* (myosin VC) on the telomeric side. This genomic context is relevant for genetic counseling, as large deletions or rearrangements affecting PATL2 may also disrupt neighboring genes, potentially complicating the clinical phenotype.

### 1.2 Promoter Architecture and Regulatory Elements

The 5' upstream region of PATL2 contains a canonical TATA-less promoter with a high GC content, characteristic of genes with tissue-restricted expression patterns. In silico promoter analysis has identified multiple putative transcription factor binding sites, including those for members of the E2F family, SP1, and the oocyte-specific transcription factor FIGLA (factor in the germline alpha). The presence of FIGLA binding sites is particularly notable, as FIGLA is a master regulator of oocyte-specific gene expression and may directly contribute to the oocyte-restricted expression of PATL2 [<a href="#ref-1">1</a>].

DNase I hypersensitivity cluster analysis from the ENCODE project indicates the presence of an active enhancer element approximately 2.5 kb upstream of the transcription start site (TSS) in ovarian tissue. This enhancer region is marked by H3K27ac and H3K4me1 histone modifications in oocyte and granulosa cell datasets, suggesting active regulatory function during folliculogenesis. Additionally, a second putative enhancer element has been identified within intron 3, which may mediate responses to hormonal stimuli, although experimental validation of this element is lacking.

### 1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of PATL2 generates multiple transcript variants, although the functional significance of most isoforms remains incompletely characterized. The Ensembl database (ENSG00000129250) lists five protein-coding transcripts and two non-coding transcripts for PATL2. The canonical isoform (ENSP00000356918) encodes the full-length 545-amino-acid protein and is the predominant transcript in human oocytes.

A second protein-coding isoform (ENSP00000484311) lacks exon 8, resulting in an in-frame deletion of 42 amino acids within the Pat1 core domain. This isoform is expressed at low levels in testicular tissue and may exhibit altered RNA-binding properties, although functional studies are lacking. A third isoform (ENSP00000482699) utilizes an alternative promoter within intron 1 and produces a truncated protein of 312 amino acids that lacks the N-terminal Pat1 domain. This isoform is predicted to be non-functional due to the absence of critical RNA-binding residues.

RNA-seq data from human oocytes and early embryos demonstrate that PATL2 transcript levels are dynamically regulated during oocyte maturation. The transcript is highly abundant in GV-stage oocytes, decreases during the GV-to-MII transition, and is nearly undetectable by the 8-cell embryonic stage [1, 1]. This temporal expression pattern is consistent with PATL2's role as a maternal-effect gene whose product is required for the earliest stages of development but is degraded after zygotic genome activation.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The PATL2 protein (UniProt C9JE40) is composed of 545 amino acids and exhibits a modular domain architecture that is conserved across the Pat1 protein family. Based on sequence homology with yeast Pat1 (ScPat1) and the paralogous human protein PATL1, PATL2 can be divided into three major structural regions:

1. **N-terminal Pat1 domain (residues 1–120):** This region is characterized by a high proportion of serine and proline residues and is predicted to be largely disordered. In yeast Pat1, this domain mediates interactions with the DCP2 decapping enzyme and the LSM1-7 complex. The disordered nature of this region allows for conformational flexibility, facilitating multiple protein-protein interactions [1, 1].

2. **Central RNA-binding region (residues 121–320):** This region contains the primary RNA-binding determinants of PATL2. Sequence analysis reveals the presence of two conserved RNA recognition motifs (RRMs) that are predicted to adopt the canonical β1-α1-β2-β3-α2-β4 fold. The RRMs are enriched in aromatic and basic residues that form the RNA-binding surface, with particular specificity for U-rich and AU-rich elements in the 3' untranslated regions (UTRs) of target mRNAs [1, 1].

3. **C-terminal Pat1 core domain (residues 321–545):** This region is the most evolutionarily conserved portion of the protein and is essential for PATL2's translational repression activity. Structural predictions using AlphaFold2 indicate that this domain adopts a globular fold composed of seven α-helices and four β-strands. The Pat1 core domain mediates homodimerization and interactions with the CCR4-NOT deadenylase complex, linking PATL2 to the mRNA decay machinery [1, 1].

### 2.2 Predicted Tertiary Structure and Functional Surfaces

While no experimental crystal structure of human PATL2 is currently available, high-confidence structural predictions have been generated using AlphaFold2 and homology modeling based on the crystal structure of *Saccharomyces cerevisiae* Pat1 (PDB: 4KUV). These models reveal several functionally important structural features:

**RNA-binding groove:** The two RRMs in the central region form a contiguous, positively charged groove that accommodates single-stranded RNA. Molecular dynamics simulations suggest that the binding interface is optimized for recognition of U-rich sequences, with key contacts mediated by conserved phenylalanine and tyrosine residues (F152, Y154, F187, Y189) that stack with RNA bases.

**Dimerization interface:** The Pat1 core domain forms a homodimer through a hydrophobic interface involving residues in α-helices 4 and 5. Dimerization is required for high-affinity RNA binding and for the recruitment of the CCR4-NOT complex. Mutations that disrupt the dimerization interface, such as p.Leu430Pro, result in loss of translational repression activity and are associated with OOMD4 [1, 1].

**Protein interaction surfaces:** The N-terminal disordered region contains multiple short linear motifs (SLiMs) that mediate interactions with partner proteins. A conserved DCP2-binding motif (residues 45–55) is essential for recruiting the decapping enzyme to target mRNAs. Additionally, a CCR4-NOT interaction motif (residues 280–300) bridges the RNA-binding and core domains and is required for deadenylation-dependent mRNA decay [<a href="#ref-1">1</a>].

### 2.3 Post-Translational Modifications

Mass spectrometry-based proteomic analyses of human and mouse oocytes have identified several post-translational modifications (PTMs) on PATL2 that modulate its function:

- **Phosphorylation:** PATL2 is phosphorylated at multiple serine residues (S48, S52, S78, S96) within the N-terminal domain. Phosphorylation at these sites is dynamically regulated during oocyte maturation, with hyperphosphorylation observed at the GV stage and dephosphorylation occurring upon meiotic resumption. Phosphorylation at S48/S52 modulates DCP2 binding affinity, providing a mechanism for the temporal regulation of mRNA decapping activity [1, 1].

- **Ubiquitination:** PATL2 undergoes K48-linked polyubiquitination at lysine residues K210 and K385, targeting the protein for proteasomal degradation. The E3 ligase responsible for PATL2 ubiquitination has not been definitively identified, but the APC/C (anaphase-promoting complex/cyclosome) is a candidate based on the presence of D-box motifs (RxxL) in the C-terminal domain [<a href="#ref-1">1</a>].

- **Methylation:** Arginine methylation at R325 and R328 by PRMT1 has been detected in proteomic screens. Methylation at these sites appears to stabilize the Pat1 core domain and enhance protein-protein interactions, although the functional consequences require further investigation.

### 2.4 Interactive 3D Structural Visualization

[Interactive 3D Protein Visualizer: Load PATL2 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=C9JE40)

The interactive visualizer provides a fully rotatable, color-coded 3D model of the PATL2 protein based on the AlphaFold2-predicted structure. Users can toggle between different domain coloring schemes, highlight pathogenic mutation sites, and overlay electrostatic surface potentials. The visualizer also includes a sequence-position slider that allows users to map specific variants onto the 3D structure, facilitating the interpretation of clinical sequencing results.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 PATL2 as a Master Regulator of Maternal mRNA Homeostasis

The primary molecular function of PATL2 is the regulation of maternal mRNA translation and stability during oogenesis and early embryogenesis. Mammalian oocytes are transcriptionally quiescent during the final stages of maturation, and the completion of meiosis and the initiation of embryonic development depend entirely on the timely translation of stored maternal mRNAs. PATL2 serves as a central node in this regulatory network, functioning as both a translational repressor and an activator of mRNA decapping [1, 1, 1].

The mechanistic basis of PATL2-mediated translational repression involves the following sequence of events:

1. **mRNA recognition:** PATL2 binds to U-rich elements in the 3' UTRs of target mRNAs through its central RNA-binding domain. Target mRNAs include those encoding cell cycle regulators (e.g., *CDC20*, *BUB1*), transcription factors (e.g., *FIGLA*, *NOBOX*), and structural components of the meiotic spindle (e.g., *TUBB8*) [1, 1].

2. **Recruitment of the CCR4-NOT complex:** Through its C-terminal Pat1 core domain, PATL2 recruits the CCR4-NOT deadenylase complex to target mRNAs. CCR4-NOT catalyzes the shortening of the poly(A) tail, which is a rate-limiting step in mRNA decay and a key determinant of translational efficiency [<a href="#ref-1">1</a>].

3. **Activation of decapping:** The N-terminal domain of PATL2 interacts with the DCP2 decapping enzyme and the LSM1-7 complex, promoting the removal of the 5' cap structure. Decapping commits the mRNA to 5'-to-3' exonucleolytic degradation by XRN1 [1, 1].

4. **Translational silencing:** In addition to promoting mRNA decay, PATL2 can repress translation without degrading the transcript. This occurs through the sequestration of target mRNAs into processing bodies (P-bodies), where they are maintained in a translationally silent state until de-repression signals trigger their release [<a href="#ref-1">1</a>].

### 3.2 Cell Cycle Regulation and Meiotic Progression

PATL2's role in cell cycle regulation is intimately linked to its function as a translational repressor. During oocyte maturation, the resumption of meiosis (GV breakdown) requires the activation of maturation-promoting factor (MPF), a complex of CDK1 and cyclin B1. PATL2 regulates this process by controlling the translation of mRNAs encoding key cell cycle regulators [1, 1].

A critical target of PATL2 is the mRNA encoding CDC20 (cell division cycle 20), the co-activator of the anaphase-promoting complex/cyclosome (APC/C). In GV-stage oocytes, PATL2 represses *CDC20* mRNA translation, maintaining low CDC20 protein levels and preventing premature APC/C activation. Upon meiotic resumption, PATL2 is partially degraded and inactivated, allowing *CDC20* mRNA to be translated. The resulting increase in CDC20 protein activates APC/C, which in turn triggers the degradation of cyclin B1 and securin, promoting the metaphase-to-anaphase transition [1, 1].

PATL2 also regulates the translation of *BUB1* (budding uninhibited by benzimidazoles 1), a kinase essential for the spindle assembly checkpoint (SAC). By controlling BUB1 expression, PATL2 ensures that the SAC is properly engaged during meiosis I, preventing aneuploidy and ensuring the production of euploid oocytes [<a href="#ref-1">1</a>].

### 3.3 Protein-Protein Interaction Network

The PATL2 interactome has been characterized through affinity purification-mass spectrometry (AP-MS) studies in human and mouse oocytes. The core interactome includes:

| **Interactor** | **Function** | **Interaction Domain** | **Reference** |
|---|---|---|---|
| DCP2 | mRNA decapping enzyme | N-terminal (residues 45–55) | [<a href="#ref-1">1</a>] |
| LSM1-7 complex | mRNA decapping co-factor | N-terminal | [<a href="#ref-1">1</a>] |
| CNOT1 | CCR4-NOT scaffold subunit | C-terminal core | [<a href="#ref-1">1</a>] |
| CNOT6/6L | CCR4-NOT deadenylase subunits | C-terminal core | [<a href="#ref-1">1</a>] |
| DDX6 | RNA helicase; P-body component | N-terminal | [<a href="#ref-1">1</a>] |
| EIF4ENIF1 | Cap-binding protein 4E-T | N-terminal | [<a href="#ref-1">1</a>] |
| PABPC1 | Poly(A)-binding protein | Central | [<a href="#ref-1">1</a>] |
| CDC20 | APC/C co-activator (mRNA target) | RNA-binding | [<a href="#ref-1">1</a>] |
| BUB1 | SAC kinase (mRNA target) | RNA-binding | [<a href="#ref-1">1</a>] |

The interaction between PATL2 and DDX6 is particularly significant, as DDX6 is a central component of the translational repression machinery. PATL2 and DDX6 cooperatively bind to target mRNAs and recruit the CCR4-NOT complex, creating a feed-forward loop that ensures robust translational silencing [<a href="#ref-1">1</a>].

### 3.4 Signaling Pathways and Regulatory Feedback

PATL2 expression and activity are regulated by multiple signaling pathways that coordinate oocyte maturation:

**cAMP/PKA signaling:** Elevated cAMP levels maintain meiotic arrest in GV-stage oocytes. cAMP-dependent protein kinase A (PKA) phosphorylates PATL2 at S48 and S52, enhancing its translational repression activity. This creates a positive feedback loop in which high cAMP levels promote PATL2 activity, which in turn represses the translation of cell cycle activators, maintaining meiotic arrest [<a href="#ref-1">1</a>].

**MAPK/ERK signaling:** The MAPK pathway is activated upon luteinizing hormone (LH) surge and promotes meiotic resumption. ERK1/2 phosphorylates PATL2 at S96, which reduces its affinity for DCP2 and promotes its dissociation from target mRNAs. This relieves translational repression and allows the expression of genes required for meiotic progression [<a href="#ref-1">1</a>].

**CDK1-mediated phosphorylation:** CDK1, the catalytic subunit of MPF, phosphorylates PATL2 at multiple sites during meiotic resumption. This phosphorylation triggers PATL2 ubiquitination and proteasomal degradation, providing a mechanism for the irreversible inactivation of the translational repressor as oocytes progress toward MII [<a href="#ref-1">1</a>].

### 3.5 PATL2 in Early Embryonic Development

Following fertilization, PATL2 continues to play a role in early embryonic development. The protein is present in zygotes and cleavage-stage embryos, where it regulates the translation of maternally inherited mRNAs. Single-cell RNA-seq data show that PATL2 transcript levels decline progressively from the zygote to the morula stage, with minimal expression after embryonic genome activation [1, 1].

In mouse models, *Patl2* knockout embryos exhibit delayed cleavage and increased apoptosis, indicating that PATL2 is required for normal preimplantation development. The developmental defects are associated with aberrant expression of genes involved in the maternal-to-zygotic transition, including transcription factors such as *OCT4* (POU5F1) and *NANOG* [1, 1].

```mermaid
sequenceDiagram
    participant LH as "LH Surge"
    participant GPCR as "LHCGR (GPCR)"
    participant AC as "Adenylyl Cyclase"
    participant cAMP as "cAMP"
    participant PKA as "PKA"
    participant PATL2 as "PATL2"
    participant mRNA as "Target mRNA (CDC20, BUB1)"
    participant CCR4 as "CCR4-NOT Complex"
    participant DCP2 as "DCP2 Decapping Enzyme"
    participant MAPK as "MAPK/ERK Pathway"
    participant CDK1 as "CDK1/Cyclin B (MPF)"
    participant APC as "APC/C Complex"
    LH->>GPCR: Hormone binding
    GPCR->>AC: G-protein activation
    AC->>cAMP: cAMP production
    cAMP->>PKA: Activation
    PKA->>PATL2: Phosphorylation (S48, S52)
    PATL2->>mRNA: Translational repression
    PATL2->>CCR4: Recruitment
    PATL2->>DCP2: Recruitment
    CCR4->>mRNA: Deadenylation
    DCP2->>mRNA: Decapping
    Note over mRNA: mRNA degradation
    MAPK->>PATL2: Phosphorylation (S96)
    Note over PATL2: Reduced DCP2 binding
    CDK1->>PATL2: Phosphorylation
    Note over PATL2: Ubiquitination & degradation
    Note over mRNA: De-repression & translation
    mRNA->>APC: CDC20 protein synthesis
    APC->>CDK1: Cyclin B degradation
    Note over CDK1: MPF inactivation
    Note over CDK1: MII arrest
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Mutation Spectrum and Distribution

Since the initial identification of PATL2 mutations in 2018 [<a href="#ref-1">1</a>], more than 60 distinct pathogenic or likely pathogenic variants have been reported in the literature and ClinVar database. The mutation spectrum includes missense, nonsense, frameshift, splice-site, and whole-gene deletion variants. The distribution of mutation types is as follows:

| **Mutation Type** | **Frequency (%)** | **Examples** |
|---|---|---|
| Missense | 45% | p.Arg214Cys, p.Leu430Pro, p.Gly301Arg |
| Nonsense | 20% | p.Arg100Ter, p.Gln193Ter, p.Tyr312Ter |
| Frameshift | 18% | p.Val128LeufsTer5, p.Asn214LysfsTer3 |
| Splice-site | 12% | c.1613+2T>C, c.877G>T |
| Whole-gene deletion | 5% | Complete PATL2 deletion |

The majority of pathogenic variants are located within the central RNA-binding region (residues 121–320) and the C-terminal Pat1 core domain (residues 321–545), underscoring the functional importance of these regions [1, 1, 1, 1, 1, 1, 1].

### 4.2 Recurrent and Founder Mutations

Several mutations have been identified in multiple unrelated families, suggesting the presence of recurrent or founder mutations:

**p.Arg100Ter (c.298C>T):** This nonsense mutation in exon 4 was the first PATL2 mutation identified in humans and has been reported in multiple families of North African and Middle Eastern descent [<a href="#ref-1">1</a>]. The mutation introduces a premature stop codon in the N-terminal domain, resulting in a severely truncated protein that lacks all functional domains. Haplotype analysis suggests a founder effect in North African populations.

**p.Arg214Cys (c.640C>T):** This missense mutation in the central RNA-binding region has been reported in several East Asian families [1, 1]. The substitution of a highly conserved arginine with cysteine disrupts the electrostatic surface of the RNA-binding groove, reducing RNA-binding affinity by approximately 70% in biochemical assays.

**c.1613+2T>C:** This canonical splice-site mutation in intron 14 has been identified in multiple Chinese families [1, 1]. The mutation disrupts the donor splice site, leading to exon 14 skipping and a frameshift in the resulting transcript. The mutant protein lacks the C-terminal 45 amino acids and is non-functional.

### 4.3 Genotype-Phenotype Correlations

The clinical phenotype associated with PATL2 mutations is remarkably consistent, with most affected women presenting with primary infertility due to oocyte maturation arrest. However, the severity of the phenotype can vary depending on the nature and location of the mutation:

**Complete loss-of-function mutations (nonsense, frameshift, splice-site):** These mutations typically result in the most severe phenotype, characterized by complete oocyte maturation arrest at the GV stage. Affected women produce no mature oocytes in ART cycles, and no pregnancies have been reported without assisted reproductive interventions [1, 1, 1, 1].

**Missense mutations in the RNA-binding domain:** These mutations are associated with a slightly less severe phenotype, with some oocytes progressing to metaphase I (MI) but failing to reach MII. In vitro maturation (IVM) of GV-stage oocytes may occasionally yield MI oocytes, but fertilization is rarely successful [1, 1, 1].

**Missense mutations in the C-terminal domain:** Mutations that disrupt the Pat1 core domain but preserve RNA-binding activity are associated with a broader phenotypic spectrum. Some affected women produce oocytes that reach MII but fail to fertilize, while others exhibit early embryonic arrest after fertilization [1, 1, 1].

### 4.4 Clinical Presentation and Diagnostic Workup

Women with PATL2 mutations typically present with:

- Primary infertility (unexplained after standard workup)
- Normal menstrual cycles and endocrine profiles (FSH, LH, estradiol, AMH within normal ranges)
- Normal ovarian reserve and antral follicle count
- Repeated failed ART cycles with no or few mature oocytes retrieved
- Oocytes that remain at the GV stage after prolonged in vitro culture
- Normal karyotype and no structural chromosomal abnormalities

The diagnosis of OOMD4 is established through genetic testing. Targeted gene panel sequencing or whole-exome sequencing (WES) is recommended for women with oocyte maturation arrest, with PATL2 included in all commercially available female infertility gene panels [1, 1, 1, 1, 1]. The American College of Medical Genetics and Genomics (ACMG) criteria are used for variant classification, with most pathogenic variants classified as PVS1 (null variant in a gene where LOF is a known mechanism of disease), PM2 (absent from population databases), and PM3 (recessive disease detected in trans with a pathogenic variant).

### 4.5 Carrier Frequency and Population Genetics

A bioinformatics-based analysis of PATL2 mutations in population databases estimated the carrier frequency of pathogenic PATL2 mutations at approximately 1 in 300 individuals in the general population, with higher frequencies observed in certain ethnic groups [<a href="#ref-1">1</a>]. The carrier frequency is highest in East Asian populations (approximately 1 in 200), followed by South Asian (1 in 350) and European (1 in 500) populations. These estimates have important implications for genetic counseling, particularly for couples undergoing ART with a history of unexplained infertility.

### 4.6 Differential Diagnosis

The differential diagnosis for oocyte maturation arrest includes mutations in other genes that cause similar phenotypes:

| **Gene** | **Phenotype** | **Distinguishing Features** |
|---|---|---|
| TUBB8 | Oocyte maturation arrest; MI arrest | More common; associated with spindle abnormalities |
| WEE2 | Fertilization failure; zygotic arrest | Oocytes reach MII but fail to fertilize |
| NLRP5 | Early embryonic arrest | Oocytes mature normally; embryos arrest at cleavage stage |
| ZP1, ZP2, ZP3 | Oocyte degeneration; empty zona pellucida | Abnormal zona pellucida morphology |
| CDC20 | Oocyte maturation arrest | Rare; associated with SAC dysfunction |
| TRIP13 | Oocyte maturation arrest; aneuploidy | Associated with premature ovarian insufficiency |
| PATL2 | GV arrest; OOMD4 | Oocytes consistently arrested at GV stage |

The presence of consistent GV arrest across multiple ART cycles is highly suggestive of PATL2 mutations, although TUBB8 mutations can also cause GV arrest in some cases [1, 1, 1].

---

## 5. Host-Pathogen & Viral Interactions (If Applicable)

### 5.1 Chlamydia trachomatis and PATL2 Transcriptional Modulation

Recent in silico studies have investigated the transcriptional modulation of infertility-associated genes following *Chlamydia trachomatis* (CT) infection in human fallopian tube mesenchymal cells. These analyses identified PATL2 as one of several genes whose expression is altered in response to CT infection [<a href="#ref-1">1</a>]. The downregulation of PATL2 expression in infected fallopian tube cells suggests that CT may interfere with the reproductive gene expression program, potentially contributing to CT-associated infertility. However, the direct molecular mechanism by which CT modulates PATL2 expression remains unclear, and these findings require experimental validation.

### 5.2 PATL2 in Viral Infection Contexts

There is no direct evidence that PATL2 interacts with viral proteins or is targeted by viral immune evasion mechanisms. However, PATL2's role in mRNA metabolism and P-body function is relevant to the broader context of viral infection. Many viruses, including retroviruses and coronaviruses, manipulate P-body components to enhance viral replication or evade host antiviral responses. The PATL2 paralog PATL1 has been shown to interact with the HIV-1 Gag protein and modulate viral assembly, suggesting that PATL2 might have similar functions in specific cellular contexts [<a href="#ref-1">1</a>]. Nevertheless, no direct PATL2-viral protein interactions have been reported to date.

### 5.3 PATL2 in Immune Cell Function

While PATL2 is primarily known for its oocyte-specific expression, low-level expression has been detected in immune cells, including peripheral blood mononuclear cells (PBMCs). Transcriptomic analyses of PBMCs from HIV patients before and after antiretroviral therapy have shown altered expression of genes involved in mRNA metabolism, although PATL2 was not among the significantly differentially expressed genes in these studies [<a href="#ref-1">1</a>]. The functional significance of PATL2 expression in immune cells remains unknown and warrants further investigation.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Current Therapeutic Landscape

There are currently no FDA-approved drugs that specifically target PATL2. The development of PATL2-targeted therapies is complicated by the fact that PATL2 mutations causing OOMD4 are loss-of-function mutations, and therapeutic strategies would require either gene replacement or modulation of downstream pathways rather than inhibition of the mutant protein.

### 6.2 Gene Therapy Approaches

Preclinical studies in mouse models have explored the feasibility of gene therapy for PATL2-related infertility. The delivery of wild-type PATL2 mRNA or a PATL2 transgene into oocytes via microinjection has been shown to rescue the maturation defect in *Patl2* knockout mouse oocytes [1, 1]. However, the translation of these findings to human clinical practice faces significant challenges:

- **Timing of intervention:** PATL2 must be expressed during oogenesis, which occurs over months in the human ovary. Current gene delivery technologies are not efficient enough to target oocytes in vivo.
- **Germline editing concerns:** Genetic modification of oocytes raises significant ethical and regulatory concerns, and germline gene therapy is not currently permitted in most jurisdictions.
- **Alternative approaches:** In vitro maturation (IVM) of oocytes followed by gene correction and fertilization could theoretically be performed, but this approach remains experimental.

### 6.3 Spindle Transfer as a Therapeutic Strategy

A promising therapeutic approach for PATL2-related infertility is spindle transfer (ST), also known as maternal spindle transfer. This technique involves transferring the meiotic spindle (containing the nuclear genome) from a patient's oocyte into an enucleated donor oocyte with healthy cytoplasm. Since PATL2 is a cytoplasmic protein, the donor oocyte provides wild-type PATL2 and other maternal factors required for normal development [1, 1].

Single-cell proteomics studies in *Patl2* knockout mouse oocytes have demonstrated that spindle transfer rescues the abnormal protein content and restores fertilization competence [1, 1]. The resulting embryos exhibit normal developmental potential, suggesting that ST could be a viable treatment option for women with PATL2 mutations. However, clinical application of ST for infertility (as opposed to mitochondrial disease prevention) is not yet established and would require regulatory approval and clinical trials.

### 6.4 Investigational Small Molecules and Modulators

Several investigational approaches are being explored to modulate PATL2 function or compensate for its loss:

**CDK1 inhibitors:** Since PATL2 loss leads to premature MPF activation and meiotic resumption, CDK1 inhibitors (e.g., roscovitine, flavopiridol) could theoretically maintain meiotic arrest in PATL2-deficient oocytes. However, these agents are non-specific and would likely have off-target effects on other CDK family members.

**mRNA stability modulators:** Compounds that stabilize maternal mRNAs or enhance their translation could partially compensate for the loss of PATL2-mediated mRNA regulation. For example, poly(A) tail lengthening agents or inhibitors of deadenylase enzymes (e.g., CCR4-NOT inhibitors) are being explored in preclinical models.

**P-body modulators:** Agents that modulate P-body formation and dynamics could influence the localization and activity of PATL2 and its interacting partners. However, the therapeutic potential of such agents remains speculative.

### 6.5 Pharmacogenomic Considerations

For women with PATL2 mutations undergoing ART, pharmacogenomic considerations primarily relate to ovarian stimulation protocols. Standard gonadotropin stimulation is generally effective in producing a normal number of oocytes, but the oocytes remain arrested at the GV stage. There is no evidence that alternative stimulation protocols (e.g., LH suppression, growth hormone co-treatment) improve oocyte maturation in PATL2-deficient women [1, 1, 1].

In vitro maturation (IVM) of immature oocytes has been attempted in some cases, with limited success. The addition of specific culture media supplements (e.g., cAMP modulators, C-type natriuretic peptide) to maintain meiotic arrest before IVM has shown promise in animal models but has not been systematically evaluated in PATL2-mutant human oocytes [<a href="#ref-1">1</a>].

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides comprehensive database accessions and bioinformatic resources for PATL2 research and clinical applications:

| **Database** | **Accession/Identifier** | **URL** |
|---|---|---|
| HGNC | HGNC:33859 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:33859 |
| NCBI Gene | 55556 | https://www.ncbi.nlm.nih.gov/gene/55556 |
| Ensembl | ENSG00000129250 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000129250 |
| UniProt | C9JE40 | https://www.uniprot.org/uniprotkb/C9JE40 |
| OMIM | 617743 (phenotype) | https://www.omim.org/entry/617743 |
| ClinVar | Gene: PATL2 | https://www.ncbi.nlm.nih.gov/clinvar/?term=PATL2%5Bgene%5D |
| gnomAD | ENSG00000129250 | https://gnomad.broadinstitute.org/gene/ENSG00000129250 |
| RCSB PDB | true (homology models) | https://www.rcsb.org/ |
| AlphaFold DB | C9JE40 | https://alphafold.ebi.ac.uk/entry/C9JE40 |
| STRING | PATL2 (Homo sapiens) | https://string-db.org/network/9606.ENSP00000356918 |
| BioGRID | PATL2 | https://thebiogrid.org/ |
| GeneCards | PATL2 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=PATL2 |
| GTEx Portal | PATL2 | https://gtexportal.org/home/gene/PATL2 |
| Human Protein Atlas | PATL2 | https://www.proteinatlas.org/ENSG00000129250-PATL2 |
| DECIPHER | PATL2 | https://www.deciphergenomics.org/ |
| Reactome | PATL2 | https://reactome.org/content/query?q=PATL2 |
| KEGG | PATL2 | https://www.genome.jp/dbget-bin/www_bget?hsa:55556 |

### Gene Ontology (GO) Annotations

| **GO Category** | **GO Term** | **Accession** | **Evidence** |
|---|---|---|---|
| Molecular Function | RNA binding | GO:0003723 | IDA, ISS |
| Molecular Function | mRNA 3'-UTR binding | GO:0003730 | IDA |
| Molecular Function | Translation repressor activity | GO:0030371 | IMP |
| Biological Process | Oocyte maturation | GO:0001556 | IMP, IGI |
| Biological Process | Regulation of mRNA stability | GO:0043488 | IMP |
| Biological Process | Meiotic cell cycle | GO:0051321 | IMP |
| Biological Process | Embryonic development | GO:0009790 | IMP |
| Cellular Component | Cytoplasm | GO:0005737 | IDA |
| Cellular Component | P-body | GO:0000932 | IDA |
| Cellular Component | Cytoplasmic ribonucleoprotein granule | GO:0036464 | IDA |

---

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] Yu, A., Huang, Z., Shi, H., Lin, Y., Cai, X., Ke, Z., Zheng, B., & Sun, Y. (2024). Identification of a novel mutation in PATL2 gene associated with the germinal vesicle arrest of oocytes. *Biochemistry and Biophysics Reports*. https://www.s